NK cell-based cancer immunotherapy: from basic biology to clinical development

被引：0

作者：

Sizhe Liu

Vasiliy Galat

Yekaterina Galat4

Yoo Kyung Annie Lee

Derek Wainwright

Jennifer Wu

机构：

[1] Northwestern University,Department of Urology, Feinberg School of Medicine

[2] Northwestern University,Department of Pathology, Feinberg School of Medicine

[3] Northwestern University Feinberg School of Medicine,Robert H. Lurie Comprehensive Cancer Center

[4] Northwestern University Feinberg School of Medicine,Department of Pediatrics, Stanley Manne Children’s Research Institute, Ann & Robert H. Lurie Children’s Hospital

[5] Emory University,Biology Program

[6] Northwestern University,Departments of Neurological Surgery, Medicine

[7] Russian Academy of Sciences,Hematology and Oncology, Microbiology

来源：

Journal of Hematology & Oncology | / 14卷

关键词：

NK cell; Cancer immunotherapy; Clinical trials; iPSC;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activation is governed by the interaction of NK receptors with target cells, independent of antigen processing and presentation. Due to relatively unsophisticated cues for activation, NK cell has gained significant attention in the field of cancer immunotherapy. Many efforts are emerging for developing and engineering NK cell-based cancer immunotherapy. In this review, we provide our current understandings of NK cell biology, ongoing pre-clinical and clinical development of NK cell-based therapies and discuss the progress, challenges, and future perspectives.

引用

共 50 条

[11] NK Cell-Based Immunotherapy in Colorectal Cancer
Della Chiesa, Mariella
Setti, Chiara
Giordano, Chiara
Obino, Valentina
Greppi, Marco
Pesce, Silvia
Marcenaro, Emanuela
Rutigliani, Mariangela
Provinciali, Nicoletta
Paleari, Laura
DeCensi, Andrea
Sivori, Simona
Carlomagno, Simona
VACCINES, 2022, 10 (07)
[12] Synthetic biology in cell-based cancer immunotherapy
Chakravarti, Deboki
Wong, Wilson W.
TRENDS IN BIOTECHNOLOGY, 2015, 33 (08) : 449 - 461
[13] The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
Kang, Synat
Gao, Xuefeng
Zhang, Li
Yang, Erna
Li, Yonghui
Yu, Li
CURRENT ONCOLOGY, 2021, 28 (02) : 1077 - 1093
[14] NK cell-based tumor immunotherapy
Zhang, Hao
Yang, Li
Wang, Tingting
Li, Zhen
BIOACTIVE MATERIALS, 2024, 31 : 63 - 86
[15] NK Cell-Based Glioblastoma Immunotherapy
Golan, Irene
Rodriguez de la Fuente, Laura
Costoya, Jose A.
CANCERS, 2018, 10 (12):
[16] miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy
Pesce, Silvia
Greppi, Marco
Ferretti, Elisa
Obino, Valentina
Carlomagno, Simona
Rutigliani, Mariangela
Thoren, Fredrik B.
Sivori, Simona
Castagnola, Patrizio
Candiani, Simona
Marcenaro, Emanuela
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
[17] Recent clinical development of dendritic cell-based immunotherapy for prostate cancer
Rini, B
EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (11) : 1729 - 1734
[18] Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy
Tarannum, Mubin
Romee, Rizwan
Shapiro, Roman M.
FRONTIERS IN IMMUNOLOGY, 2022, 13
[19] Toward the next generation of NK cell-based adoptive cancer immunotherapy
Ni, Jing
Miller, Matthias
Stojanovic, Ana
Cerwenka, Adelheid
ONCOIMMUNOLOGY, 2013, 2 (04)
[20] NK Cell-Based Immunotherapy for Hematological Malignancies
Sivori, Simona
Meazza, Raffaella
Quintarelli, Concetta
Carlomagno, Simona
Della Chiesa, Mariella
Falco, Michela
Moretta, Lorenzo
Locatelli, Franco
Pende, Daniela
JOURNAL OF CLINICAL MEDICINE, 2019, 8 (10)

← 1 2 3 4 5 →